In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
News|Podcasts|March 27, 2026
ACT Brief: CRO Selection as Incentive Design, Integrated Tech Stack Strategy, and Pricing Disruption in Pharma
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine how game theory principles can improve CRO and vendor selection through ecosystem alignment, why clinical technology platforms must be purpose-built and fully integrated, and how pricing pressures and regulatory changes are reshaping pharmaceutical R&D investment.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a new contributed
article , the authors presented a game-theoretic framework for CRO and vendor selection based on science-first qualification, ecosystem formation, mechanism-designed procurement, and outcome-aligned contracting. Rather than traditional vendor evaluation, this approach treats selection as incentive design where truthful disclosure and collaboration become optimal strategies for all parties, creating conditions for genuine partnership.
- In part one of a new video
interview , Cheryl Kole, vice president of solution strategy and commercialization at Almac Clinical Technologies, discussed why an effective clinical tech stack must be purpose-built, fully integrated, and designed to simplify research execution rather than add complexity across fragmented platforms. - In a new
interview from Pharmaceutical Technology, Tony Lakavage, executive vice president and head of global external affairs at USP, addressed mega trends including IRA-driven price negotiations, Most Favored Nation initiatives, and FDA's revised biosimilar guidance allowing analytical data instead of costly clinical efficacy trials. Together, these changes are reshaping R&D investment and manufacturing strategies while accelerating biosimilar market entry.
That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
Hierarchical Endpoints in Cardiology: How Much Treatment Benefit, and From Where
3
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
4
What ClinOps Professionals Just Starting With AI Should Keep Top of Mind
5